Loading
Track FGFR2 resistance mutations in blood and switch to the next-generation inhibitor that still covers them, before the scan shows progression.
In biliary tract cancer driven by FGFR2 fusions, resistance to pemigatinib and futibatinib arises through polyclonal FGFR2 kinase-domain mutations that appear in cell-free DNA weeks before scans show progression. The idea is to monitor plasma ctDNA serially and switch pre-emptively to a next-generation inhibitor such as tinengotinib or lirafugratinib that still covers the emerging mutation. The rationale is that these resistance mutations are drug-specific and predictable, and molecular progression precedes clinical progression. The proposed test is a randomised phase 2 of ctDNA-triggered versus imaging-triggered switching with time to chemotherapy as the endpoint, at an early clinical stage, bearing on the liquid biopsy and kinase inhibitor technologies and the FGFR2 target.
One of the most cited reviews Europe PMC returns for FGFR2 in Biliary tract cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for FGFR2 in Biliary tract cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for FGFR2 in Biliary tract cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma, FIRST-308, Tinengotinib, Biliary tract cancer (cholangiocarcinoma).
Shares FGFR2 fusions and rearrangements, Futibatinib, Pemigatinib, FGFR2.
Shares Futibatinib, FGFR2, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma).
Shares FIGHT-202, Pemigatinib, Intrahepatic cholangiocarcinoma.
Shares Futibatinib, Pemigatinib, FGFR2, Biliary tract cancer (cholangiocarcinoma).
Shares Pemigatinib, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
Shares Pemigatinib, Intrahepatic cholangiocarcinoma, Biliary tract cancer (cholangiocarcinoma), Small-molecule kinase inhibitors.
Shares A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA), Biliary tract cancer (cholangiocarcinoma).